T2 Biosystems Announces Meta-analysis of Controlled Studies in Peer-Reviewed Medical Journal Highlighting the Benefits of T2M...
April 27 2021 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced that Expert
Review of Medical Devices, a peer-reviewed medical journal,
published meta-analysis findings confirming that utilization of T2
Biosystems’ Magnetic Resonance (T2MR®) technology for
identification of bloodstream infections (BSIs) provides faster
time to detection, faster transition to targeted microbial therapy,
faster de-escalation of empirical therapy, and shorter Intensive
Care Unit (ICU) and hospital stay, and with comparable mortality
rate versus the current blood culture standard.
Study authors of the meta-analysis, “Antimicrobial and Resource
Utilization with T2 Magnetic Resonance for Rapid Diagnosis of
Bloodstream Infections: Systematic Review with Meta-analysis of
Controlled Studies,” systematically searched MEDLINE, EMBASE, and
CENTRAL for randomized trials or observational controlled studies
of patients with suspected BSIs receiving a diagnosis with T2MR or
blood culture, ultimately including 14 studies. Key meta-analysis
results include:
- Significant
reduction in the time to detection (MD=-81 hours) and time to
species identification (MD=-77 hours) with T2MR vs. blood
culture
- Patients testing
positive on T2MR received targeted antimicrobial therapy faster
(MD=-42 hours); and patients testing negative on T2MR were
de-escalated from empirical therapy faster (MD=-7 hours) vs. blood
culture.
- Length of ICU stay (MD=-5.0 days) and hospital stay (MD=-4.8
days) were shorter with T2MR vs. blood culture
“This analysis reinforces the clinical benefits of our
technology compared to blood culture for BSI diagnosis and
management,” said Aparna Ahuja MD, Chief Medical Officer at T2
Biosystems. “This provides compelling evidence that T2MR technology
enables faster targeted treatment which can have a significant
positive impact on patient care, antimicrobial stewardship and cost
management for hospitals that adopt it as part of their sepsis
protocols.” Current
standard of care for patients suspected of BSIs or sepsis requires
1-7 days to provide species ID and susceptibility results. This
information is used by clinicians to target therapy and optimize
treatment of the identified infectious pathogen. T2 Biosystems’
T2Bacteria® and T2Candida® Panels are the first and only FDA
cleared products able to provide results directly from whole blood
in three to five hours, often before the second dose of empiric
antibiotic therapy is administered, without the need to wait days
for a positive blood culture.
The time-savings associated with T2MR technology provide
meaningful clinical and economic value for patients and hospitals.
As identified by the meta-analysis, ICU stay and hospital stay
were, on average, five days shorter in patients receiving a
diagnosis with the T2MR panels as compared to blood cultures. The
authors conclude that in addition to significant clinical
improvements and efficiencies, this could theoretically reduce
hospital costs by up to $25,000 per patient tested.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and
the T2SARS-CoV-2™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2CaurisTM Panel, and
T2Lyme TM Panel, as well as additional products for the detection
of bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the ability of
the T2MR panel to provide meaningful clinical and economic value
for patients and hospitals, as well as statements that include the
words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”,
“estimate,” “may,” “should,” “anticipate,” and similar statements
of a future or forward looking nature. These forward-looking
statements are based on management's current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, (i) any inability to (a)
realize anticipated benefits from commitments, contracts or
products; (b) successfully execute strategic priorities; (c) bring
products to market; (d) expand product usage or adoption; (e)
obtain customer testimonials; (f) accurately predict growth
assumptions; (g) realize anticipated revenues; (h) incur expected
levels of operating expenses; or (i) increase the number of
high-risk patients at customer facilities; (ii) failure of early
data to predict eventual outcomes; (iii) failure to make or
obtain anticipated FDA filings or clearances within expected time
frames or at all; or (iv) the factors discussed under Item 1A.
"Risk Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2019, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 16, 2020, and other filings
the Company makes with the SEC from time to time. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
the Company may elect to update such forward-looking statements at
some point in the future, unless required by law, it disclaims any
obligation to do so, even if subsequent events cause its views to
change. Thus, no one should assume that the Company’s silence over
time means that actual events are bearing out as expressed or
implied in such forward-looking statements. These forward-looking
statements should not be relied upon as representing the Company's
views as of any date subsequent to the date of this press
release.
Media Contact:Amanda Michelson, Vault
Communicationsamichelson@vaultcommunications.com 609-417-7077
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024